Trial Profile
An Open-label, Phase I, Single Administration, Dose- Escalation Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 May 2014
Price :
$35
*
At a glance
- Drugs Pigment epithelium derived factor gene therapy (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors GenVec
- 28 May 2014 New trial record